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S U M M A R Y
Therapeutic options for progressive multifocal leukoencephalopathy (PML) caused by reactivation of
John Cunningham virus (JCV) are limited and inefﬁcient in preventing neurological progression and
death. The current study investigated the course of JCV reactivation resulting in PML in patients
undergoing allogeneic stem cell transplantation (allo-SCT) and assessed the feasibility and potential
signiﬁcance of preemptive JCV detection in peripheral blood, enabling early cessation of immunosup-
pressive therapy and immune restoration. Two allografted patients were diagnosed with PML at 188 and
808 days post-allo-SCT. Stored DNA samples of both patients, originally obtained for quantitative
cytomegalovirus PCR analysis since transplantation, were evaluated for JCV. JCV reactivation in
peripheral blood was found to precede the appearance of neurological symptoms by 126 and 105 days.
JCV blood levels were found to be highly correlated with the steroid dosage administered for treating
graft-versus-host disease (GVHD). In one patient, the cessation of immunosuppression, including
steroids, led to the disappearance of JCV in peripheral blood, with a remarkable improvement in
neurological symptoms. In conclusion, the current study suggests the feasibility of early detection of JCV
reactivation in blood. Immune restoration at that point may prevent PML development; however
prospective studies are warranted to elucidate these issues.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Progressive multifocal leukoencephalopathy (PML) is an almost
universally fatal demyelinating disease of the central nervous
system, caused by JCV reactivation in the presence of signiﬁcant
immunodeﬁciency. PML has been reported in HIV patients and
non-HIV immunocompromised patients, including those under-
going allo-SCT.1
Therapeutic options in PML, including antivirals (acyclovir,
cidofovir), antimalarials (meﬂoquine), and chemotherapeutic* Corresponding author. Tel.: +972 4 854 2541; fax: +972 4 854 2343.
E-mail addresses: s_kamenetsky@rambam.health.gov.il, irit_avivi@hotmail.com
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http://dx.doi.org/10.1016/j.ijid.2014.03.1381
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).agents (cytarabine), as well as psychiatric medications (chlor-
promazine, mirtazapine) and immunostimulants (interleukin 2,
beta-interferon), have a very limited effect.1
Immune reconstitution has been claimed to lead to resolution
of PML. The employment of a preemptive approach for the early
detection of JCV reactivation2 that could justify early cessation of
immunosuppression in feasible cases, may promote immune
restoration and prevent PML.
The current study investigated the course of JCV reactivation in
patients undergoing allo-SCT, from ﬁrst detection of JCV in
peripheral blood to the development of a full-blown neurological
disease, focusing on the association between the intensity of
immunosuppression and blood JCV levels and the clinical
signiﬁcance of early cessation of immunosuppression for the
PML course.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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2.1. Patients
The study was approved by the Institutional Review Board of
the Rambam Health Care Campus (approval number RMB 0097-
12). Two of 163 patients who underwent allo-SCT at Rambam
between 2010 and 2012 were diagnosed with PML. They presented
with new neurological symptoms, a magnetic resonance imaging
(MRI) scan of typical PML brain lesions (diffuse subcortical lesions,
characterized by hyperintense areas in T2-weighted images),
blood and cerebrospinal ﬂuid (CSF) PCR tests positive for JCV, and
the absence of another etiology explaining these clinical ﬁndings.
Six additional patients who presented with various neurologi-
cal symptoms during that period underwent a blood PCR test for
JCV, without eventually developing PML, and were included in our
study.
2.2. Retrospective analysis for JCV
CSF and stored whole blood samples of both patients, originally
taken once weekly as part of the routine cytomegalovirus PCR
surveillance strategy, were evaluated for occult JCV reactivation
using a quantitative real-time PCR for JCV DNA.3
DNA was extracted from patient samples (200 ml of whole
blood or CSF) using the Magna Pure LC apparatus and Magna Pure
LC Total Nucleic Acid Isolation Kit reagents (Roche Diagnostics,
Germany). Extracted DNA was ampliﬁed using TaqMan real-time
PCR.3 Primers and probes were derived from nucleotide sequences
of the N terminus of the T antigen of JCV. PCR was performed in a
total volume of 25 ml containing Absolute Blue QPCR Mix (Thermo
Scientiﬁc, UK) in the presence of 10 ml target DNA, 300 nM of each
primer, and 200 nM of the probe, using the Rotor-Gene 3000 or
6000 instrument (Corbett Research/Qiagen, Hilden, Germany),
under the following conditions: 15 min at 95 8C, 45 cycles of 15 s atFigure 1. JCV load dependent on time from transplant and steroid dose. (A) Patient 
progressively, approaching 25 000 000 copies/ml on day 246 following allograft, when
decline, to zero, in JCV load in blood. The arrows denote the day cidofovir was started95 8C and 60 s at 60 8C. For quantitative analysis, an average
standard curve was constructed using quantiﬁed JCV DNA
(Advanced Biotechnology Industry). Results were reported as
the number of JCV genome copies per milliliter of blood. The lowest
detection level of the test is 100 genomic copies per milliliter.
3. Results
3.1. Patient characteristics, clinical course, and outcome
Patient 1, a 48-year-old male, underwent a reduced-intensity
matched sibling allograft for advanced non-Hodgkin lymphoma
(NHL). His post-transplant course was complicated by opportu-
nistic infections and graft-versus-host disease (GVHD), requiring
prolonged immunosuppression (prednisone, tacrolimus, and
mycophenolate mofetil (MMF)). On day 188 post-allo-SCT, the
patient developed confusion, disorientation, and ataxia and was
diagnosed with PML (Figure 1). Despite the administration of
liposomal cidofovir and immunosuppression withdrawal,
the patient continued to deteriorate and died within less than
2 months after PML diagnosis.
Patient 2, a 47-year-old male, was diagnosed with acute
myeloid leukemia, for which he received daunorubicin and Ara-C
induction, high-dose Ara-C (HiDAC) consolidation, and allo-SCT
from a matched sibling, performed at ﬁrst complete remission. His
post-transplant course was complicated by a secondary graft
failure (occurring 10 months later), for which the patient received a
donor lymphocyte infusion and achieved resumption of hemato-
poiesis. He also developed acute GVHD, managed with tacrolimus
and MMF. Twenty-seven months post-transplant, the patient
presented with signs of acute dementia, sensory dysphasia, and
loss of control of sphincter function, and required a wheelchair due
to severe progressive weakness in both lower extremities. Detailed
evaluation conﬁrmed the diagnosis of PML. Immunosuppression
was discontinued and the patient received three sequential doses1: The JCV level, initially detected in blood on day 90 post-transplant, increased
 he died. (B) Patient 2: Immunosuppression cessation was followed by a dramatic
.
I. Avivi et al. / International Journal of Infectious Diseases 26 (2014) 107–109 109of intravenous cidofovir, administered every 2 weeks, in conjunc-
tion with oral meﬂoquine once weekly, for almost a year. The
patient’s condition improved gradually; he is currently 52 months
post-allograft (25 months after PML diagnosis), with almost no
residual neurological sequelae, apart from mild cognitive non-
progressive dysfunction.
3.2. Retrospective analysis of JCV reactivation in peripheral blood
The two patients were diagnosed with PML at 188 days (patient
1) and 808 days (patient 2) after allograft. Quantitative molecular
assessment of periodically drawn blood samples, stored since
transplantation, showed persistent reactivation of JCV, preceding
the development of neurological symptoms by 126 and 105 days,
respectively. Remarkably, the JCV copy number in blood was found
to be directly correlated with the steroid dosage, demonstrating a
remarkable reduction in viral load following steroid cessation
(Figure 1).
Six additional patients presenting with confusion (n = 3),
drowsiness (n = 1), and psychosis (n = 1) underwent a blood PCR
test for JCV. Two of these patients (one with confusion and one
with psychosis) exhibited JCV viremia (5000 copies/ml and 24 837
copies/ml, respectively), which resolved in both patients in
response to steroid withdrawal and was accompanied with
complete resolution of neurological symptoms. The second
patient, however, died 33 days later due to overwhelming sepsis.
The four remaining patients had a negative PCR for JCV and were
diagnosed and treated for other neurological complications.
4. Discussion
In the absence of effective medications for PML, restoration of
immune function, providing an anti-JCV response, has been
suggested as the most promising therapeutic approach,4 especially
if applied at early stages of infection. Thus, preemptive detection of
persistent JCV reactivation may be important, allowing a faster
withdrawal of immunosuppression, at least in suitable allografted
patients in whom GVHD is successfully controlled.
The current report demonstrates PML to be preceded by a
relatively long subclinical reactivation period, of about 6 months,
during which JCV progressively proliferated in peripheral blood.
However, there appears to be no correlation between time of
initiation of viral shedding after transplantation and the risk of
developing clinically signiﬁcant PML, although the correlation
with shedding persistency could exist.
The decrease in JCV load might be in correlation with the
steroid dosage, even though it could reﬂect the initiation of
cidofovir. The cessation of immunosuppressive treatment in the
second patient resulted in a dramatic reduction in JCV load in
peripheral blood and clinical resolution of PML.
An attempt to withdraw immunosuppression in the ﬁrst patient
also led to an initial four-fold reduction in JCV load in peripheral
blood, but with no neurological improvement, most probably
reﬂecting the development of immune reconstitution inﬂamma-
tory syndrome, resulting in local inﬂammation and clinical
deterioration. These symptoms could be attenuated by co-
administration of steroids (an undesirable approach considering
its adverse effect on viral growth), or, as has been suggested
recently, by co-administration of a CXCR5 antagonist.5 Resumptionof immunosuppression was accompanied by an immediate
increase in viral load and continued neurological deterioration.
The ﬁnding of an apparent association between JCV load and
steroid dosage concurs with several other reports suggesting an
inverse correlation between JCV load and cellular immune
dysfunction (e.g., following natalizumab).6
Interestingly, a study performed in the HIV setting reported
clinical improvement in some patients receiving steroids, although
not translated into a survival beneﬁt; hence it is likely to reﬂect a
steroid-induced reduction in the inﬂammatory process accompa-
nying immune restoration.
Notably, information regarding the correlation between JCV
PCR blood levels and PML clinical course is limited. Data obtained
for other infections, like the BK-polyomavirus and cytomegalovi-
rus, showing that clinical improvement is accompanied by a viral
load reduction, support our observation regarding the correlation
between the JCV load dynamics and the PML clinical course.
Nevertheless, a remarkable difference in blood JCV levels between
the two PML patients, and the anecdotal detection of JCV viremia in
subjects who did not develop PML, suggest that viremia, even if at
high level, may not necessarily indicate PML development.
However, persistency of viremia, reﬂecting a failure in viral
clearance,6 could predict PML development. Nevertheless, high JCV
levels in patients with conﬁrmed PML may indicate an advanced
stage of infection. The lack of correlation between viral load and
PML development also indicates the importance of neurotropism
and virulence activity, related to the speciﬁc subtype of JCV, which
is associated with consecutive mutations.
The likelihood of developing clinically active PML following
persistent JCV viremia remains undetermined; hence the signiﬁ-
cance of preemptive detection of persistent JCV viremia is unclear.
Still, the presented cases demonstrate that early, pre-symptomatic
detection of JCV, preceding PML development by months, might be
valuable, supporting the de-escalation of immunosuppression in
patients in whom this strategy is clinically feasible.
Prospective studies are warranted to further explore promoter
drivers involved in the development of transplant-related PML and
to determine the role of a preemptive detection approach in
patients exhibiting a high immune deﬁciency proﬁle.
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